Cholesterol Lowering and Residual Risk in Diabetes, Type 1
This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This stu...
Age: 18 - 89 years
Gender: All
The GORE® VIAFORT Vascular Stent Iliofemoral Study
This study is a prospective, non-randomized, multicenter, single-arm, clinical study to
evaluate the performance, safety and efficacy of the GORE® VIAFORT Vascular Stent for
treatment of symptomatic iliofemoral venous obstruction.
Age: 18 years - 66+
Gender: All
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen
implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at
the time of surgical creation of an arteriovenous fistula for hemodialysis vascular a...
Age: 65 years - 66+
Gender: All
The GORE® VIAFORT Vascular Stent IVC Study
This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the
performance, safety, and efficacy of the GORE® VIAFORT Vascular Stent for treatment of
symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruct...
Age: 18 years - 66+
Gender: All
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
A prospective, single-arm, multi-center study designed to gather additional information on
the LimFlow System.
Age: 18 - 95 years
Gender: All
SELUTION4SFA Trial
This study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared
to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD)
in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Age: 18 years - 66+
Gender: All
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or
ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of
ischemic stroke, intracerebral hemorrhage, or vascular death.
Age: 30 years - 66+
Gender: All
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
The purpose of this research study is to determine the potential benefits of adding
information on patients' breast arterial calcification (BAC) results to the standard results
letter women receive after mammography. In addition to looking for potential breast cance...
Age: 40 years - 66+
Gender: Female
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations
previously not represented in Peripheral Vascular Disease (PVD) trials, health economics
data, and to support the safe use of commercially available Boston Scientific Corpor...
Age: 18 years - 66+
Gender: All
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry,
is to serve as an internationally collaborative, multicenter registry coordinated by an
experienced and centralized coordinating center in an effort to increase the pace of...
Age: 18 years - 66+
Gender: All
Macular Vessel Density and Foveal Avascular Zone Changes in Exfoliation Glaucoma vs Primary Open Angle Glaucoma vs Exfoliation Syndrome: An Optical Coherence Tomography Angiography Study
Glaucoma is an eye disease that results in damage to cells in the back of the eye known as the retina and poses a major risk to global public health. Primary open angle glaucoma (POAG) is the most common type of glaucoma in the United States. Exfoliation syndrome (XFS) ...
Age: 40 - 90 years
Gender: All
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants
with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Age: 18 years - 66+
Gender: All
OT-58 as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency
Homocystinuria caused by Cystathionine Beta-Synthase (CBS) Deficiency is a rare
autosomal-recessive metabolic condition characterized by an excess of homocysteine (Hcy) in
the plasma, tissues and urine. It is due to reduced or absent activity of the CBS enzyme, and
...
Age: 12 - 65 years
Gender: All
Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device
The purpose of this study is to demonstrate effectiveness and safety of the CODMAN
ENTERPRISE® Vascular Reconstruction Device and Delivery System.
Age: 21 - 70 years
Gender: All
Defining the Basis of Fibromuscular Dysplasia (FMD)
The purpose of this study has evolved and expanded since its inception. Originally the intent
was to establish the functional, molecular and genetic profile of fibroblasts from
Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects....
Age: 18 years - 66+
Gender: All
Discharge Educational Strategies for Reduction of Vascular Events
DESERVE is a discharge education study using health workers to enroll and randomly assign 800
subjects diagnosed with TIA, or mild stroke to either risk factor education or usual care.
Those patients assigned to education will receive stroke preparedness education plu...
Age: 18 years - 66+
Gender: All